A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Obsessive-compulsive disorder patients who do not improve sufficiently after treatment with a selective serotonin reuptake inhibitor might improve further if other drugs were added to the treatment regimen. The authors present a double-blind, placebo-controlled trial comparing the efficacy of adding quetiapine or clomipramine to a treatment regimen consisting of fluoxetine. Between May 2007 and March 2010, a total of 54 patients with a primary diagnosis of obsessive-compulsive disorder, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, and a current Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of at least 16, the score having dropped by less than 35% after fluoxetine monotherapy, were allocated to 1 of 3 arms (n = 18 per arm): quetiapine + fluoxetine (≤200 and ≤40 mg/d, respectively), clomipramine + fluoxetine (≤75 and ≤40 mg/d, respectively), or placebo + fluoxetine (≤80 mg/d of fluoxetine). Follow-up was 12 weeks. The Y-BOCS scores were the main outcome measure. No severe adverse events occurred during the trial, and 40 patients (74%) completed the 12-week protocol. The Y-BOCS scores (mean [SD]) were significantly better in the placebo + fluoxetine and clomipramine + fluoxetine groups than in the quetiapine + fluoxetine group (final: 18 [7] and 18 [7], respectively, vs 25 [6], P < 0.001) (reduction from baseline: -6.7 [confidence interval {CI}, -9.6 to -3.8; and -6.5 [CI, -9.0 to -3.9], respectively, vs -0.1 [CI, -2.9 to 2.7], P < 0.001; number needed to treat = 2.4). The clomipramine-fluoxetine combination is a safe and effective treatment for fluoxetine nonresponders, especially those who cannot tolerate high doses of fluoxetine. However, the period of monotherapy with the maximum dose of fluoxetine should be extended before a combination treatment strategy is applied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
Assessment of social adjustment by patient self report.
Weissman, M. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090101010 · Cited by 1,782
The Brown assessment of beliefs scale: Reliability and validity
Eisen, J. L., Phillips, K. A., Baer, L., Beer, D. A., Atala, K. D., & Rasmussen, S. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.102 · Cited by 705 · cited 2×
“At the initial evaluation, patients were interviewed by researchers trained in the application of the following instruments: Y-BOCS(29,30); Clinical Global Impression of Improvement (CGI-I) scale(31); Beck Depression Inventory (BDI)(32); Beck Anxiety Inventory (BAI)(33); Social Adjustment Scale-Self Report (SAS-SR)(34…”
MethodBloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635 · cited 2×
“The use of antipsychotics combined with SRIs is listed as a second-line treatment strategy in international treatment guidelines(10,11) and is the only such strategy that has proven effective according to meta-analyses.(12,13) The addition of an antipsychotic to the treatment regimen has been associated with meaningfu…”
BackgroundMeyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 1×
“In addition, increasing the fluoxetine dose to greater than 40 mg/d is associated with only a small increase in transporter occupancy.(25) Because of the pharmacokinetic interactions between fluoxetine and clomipramine, a 40-mg/d dose of fluoxetine should still result in a significant increase in plasma clomipramine l…”
BackgroundPsychological treatment of obsessive–compulsive disorder: A meta-analysis
Rosa-Alcázar, A. I., Sánchez-Meca, J., Gómez-Conesa, A., & Marín-Martínez, F. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2008.07.001 · Cited by 444
The social costs of anxiety disorders
Leon, A. C., Portera, L., & Weissman, M. M. (1995) · British Journal of Psychiatry · doi:10.1192/s0007125000293355 · Cited by 335 · cited 1×
“It is associated with functional losses, impaired quality of life, and a high family burden, contributing significantly to the social costs related to anxiety disorders.(4) First-line treatment options, which include serotonin reuptake inhibitors (SRIs), as well as cognitive behavioral therapy with exposure and respon…”
BackgroundMeta-analysis of the dose-response relationship of SSRI in obsessive–compulsive disorder
Bloch, M. H., McGuire, J., Landeros-Weisenberger, A., Leckman, J. F., & Pittenger, C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.50 · Cited by 317
Denys, D., de Geus, F., van Megen, H. J. G. M., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0803 · Cited by 248
Carey, P. D., Vythilingum, B., Seedat, S., Muller, J. E., van Ameringen, M., & Stein, D. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-5 · Cited by 133 · cited 1×
“15,19 Indeed, the highest rates of response to placebo were observed in the study with only 6 weeks of follow-up with a SSRI before enrollment for augmentation with quetiapine.(15) Also, for OCD patients, some authors advocate aiming for the highest well-tolerated dose of an SSRI, up to the conventional limit.”
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Stein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Self-citationDold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Early intervention for obsessive compulsive disorder: An expert consensus statement
Fineberg, N. A., Dell'Osso, B., Albert, U., Maina, G., Geller, D., Carmi, L., Sireau, N., Walitza, S., Grassi, G., Pallanti, S., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.002 · Cited by 158
Self-citationVeale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0317-5 · Cited by 162
Metadata
- Authors
- Diniz, J. B., Shavitt, R. G., Fossaluza, V., Koran, L., Pereira, C. A. D. B., & Miguel, E. C.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2011-12
- Volume
- 31
- Issue
- 6
- Pages
- 763-768
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2077907216
- Cited by
- 73
- References
- 13
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder. https://app.cochat.ai/papers/10.1097/jcp.0b013e3182367aee
- The paper
- Diniz, J. B., Shavitt, R. G., Fossaluza, V., Koran, L., Pereira, C. A. D. B., & Miguel, E. C. (2011). A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3182367aee
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.